ocrelizumab
E518760
disease-modifying therapy
humanized monoclonal antibody
monoclonal antibody
multiple sclerosis medication
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ocrelizumab canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T5425243 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ocrelizumab Context triple: [relapsing-remitting multiple sclerosis, treatedWith, ocrelizumab]
-
A.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
E.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ocrelizumab Target entity description: Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
A.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
E.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
humanized monoclonal antibody ⓘ monoclonal antibody ⓘ multiple sclerosis medication ⓘ |
| approvedFor | adults ⓘ |
| ATCCode | L04AA36 ⓘ |
| belongsToClass | IgG1 monoclonal antibodies ⓘ |
| bindingTargetLocation | B lymphocytes NERFINISHED ⓘ |
| CASNumber | 679818-59-8 ⓘ |
| commonAdverseEffect |
headache
ⓘ
herpes virus infections ⓘ infusion-related reactions ⓘ upper respiratory tract infections ⓘ |
| contraindication | active hepatitis B infection ⓘ |
| developer |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| dosingInterval | every 6 months ⓘ |
| effectOnImmuneSystem | selective depletion of CD20-expressing B cells ⓘ |
| FDAApprovalYear | 2017 ⓘ |
| halfLife | approximately 26 days ⓘ |
| hasBrandName | Ocrevus NERFINISHED ⓘ |
| indication |
active secondary progressive multiple sclerosis
ⓘ
primary progressive multiple sclerosis ⓘ relapsing forms of multiple sclerosis ⓘ relapsing-remitting multiple sclerosis NERFINISHED ⓘ |
| initialDoseRegimen | two 300 mg intravenous infusions 2 weeks apart ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| maintenanceDose | 600 mg intravenous infusion every 6 months ⓘ |
| mechanismOfAction |
B cell depletion
ⓘ
antibody-dependent cell-mediated cytotoxicity ⓘ complement-dependent cytotoxicity ⓘ |
| pharmacologicClass |
immunomodulator
ⓘ
selective immunosuppressant ⓘ |
| reduces |
MRI lesion activity in multiple sclerosis
ⓘ
multiple sclerosis relapse rate ⓘ |
| regulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| requires |
premedication with corticosteroids and antihistamines before infusion
ⓘ
screening for hepatitis B virus before initiation ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| slows | disability progression in multiple sclerosis ⓘ |
| targets |
CD20 antigen
NERFINISHED
ⓘ
CD20-positive B cells ⓘ |
| UNII | D2RT4KQ1E4 ⓘ |
| warning |
increased risk of infections
ⓘ
possible increased risk of malignancy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ocrelizumab Description of subject: Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.